MADRIGAL PHARMACEUTICALS, INC. Deferred Tax Liabilities, Unrealized Gains on Trading Securities
MADRIGAL PHARMACEUTICALS, INC. (MDGL) had Deferred Tax Liabilities, Unrealized Gains on Trading Securities of $117.00 thousand as of 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities · last filed 2026-02-19
- 2025-12-31: Deferred Tax Liabilities, Unrealized Gains on Trading Securities $117.00K.
- 2024-12-31: Deferred Tax Liabilities, Unrealized Gains on Trading Securities $117.00K.
- 2023-12-31: Deferred Tax Liabilities, Unrealized Gains on Trading Securities $117.00K.
- 2022-12-31: Deferred Tax Liabilities, Unrealized Gains on Trading Securities $0.00.
| Period end | Deferred Tax Liabilities, Unrealized Gains on Trading Securities | Deferred Tax Liabilities, Unrealized Gains on Trading Securities as first filed |
|---|---|---|
| 2025-12-31 | $117.00K 10-K · filed 2026-02-19 | |
| 2024-12-31 | $117.00K 10-K · filed 2026-02-19 | |
| 2023-12-31 | $117.00K 10-K · filed 2026-02-19 | |
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 | |
| 2021-12-31 | $0.00 10-K · filed 2024-02-28 | |
| 2020-12-31 | $14.00K 10-K/A · filed 2023-03-03 | |
| 2019-12-31 | $62.00K 10-K · filed 2022-02-24 | |
| 2016-12-31 | $13.00K 10-K · filed 2019-02-27 | $12.74K 10-K · filed 2017-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |